Andrew Badrot, C2 PHARMA CEO, is interviewed by MJH Life Sciences during CPhI 2022 in Frankfurt and discusses the future of the company and the CMO industry in general Posted on 24. November 202222. December 2022 by admin
Sarah Breen, Senior Quality Manager at C2 PHARMA, shares her thoughts on supplier oversight with Susan Haigney from Pharmaceutical Technology Posted on 21. November 2022 by admin
C2 PHARMA Expands Ophthalmic API Portfolio with Tropicamide Launch & Multiple Regulatory Filings Posted on 18. October 202218. October 2022 by admin
Pharmaceutical reshoring: a healthy requirement, a strategic necessity – a Manufacturing Chemist Featured Story Posted on 16. April 20213. October 2022 by admin
Andrew Badrot, C2 PHARMA CEO, speaks on working to mitigate risks for future crises like the COVID-19 pandemic Posted on 18. December 20203. October 2022 by admin
Interview with Andrew Badrot, C2 PHARMA CEO, a “Lëtzebuerger Merkur” Featured Story Posted on 19. November 20203. October 2022 by admin
C2 PHARMA Finalist in Excellence in Pharma: Sustainability, the CPhI Pharma Awards 2020 Posted on 23. September 20203. October 2022 by admin
The Impact of Covid-19 on the Pharmaceutical Industry Posted on 31. August 20203. October 2022 by admin
Connecting industry across the globe, a Chemicals Knowledge featured story Posted on 27. August 20203. October 2022 by admin
Andrew Badrot, CEO of C2 PHARMA, speaks on how the pharma industry has responded to the COVID-19 pandemic, a Pharma’s Almanac Q2 issue Posted on 1. July 20203. October 2022 by admin
Lessons from a modern-day pandemic: redesigning the pharmaceutical supply chain, a Manufacturing Chemist featured story Posted on 15. May 20203. October 2022 by admin
COVID-19/Coronavirus is reshaping the pharmaceutical supply chain Posted on 27. April 20203. October 2022 by admin
C2 PHARMA Opens Government and Research Access to Safety Stock of DIGOXIN API for Use in Potential COVID-19/Coronavirus Combination Treatment Posted on 26. March 20203. October 2022 by admin
Andrew Badrot, CEO of C2 PHARMA, weighs in on the future trends of mergers and acquisitions in the life sciences industry Posted on 19. March 20203. October 2022 by admin
Fairness in the pharma supply chain key to success in today’s business climate Posted on 9. January 20202. October 2020 by admin
Andrew Badrot, CEO of C2 PHARMA, speaks on developing technologies that will have the greatest impact on the biopharma industry in 2020 and beyond, a Pharma’s Almanac Q4 issue Posted on 6. December 201923. February 2021 by admin
C2 PHARMA Continues to Expand API Portfolio with Digoxin Micronized Grade, Homatropine Hydrobromide and Multiple Products Under Tech Transfer and Development Posted on 4. November 201916. June 2021 by admin
C2 PHARMA leverages virtual manufacturing to build secure supply chains, a Chemicals Knowledge featured story Posted on 2. September 201923. February 2021 by admin
Building resilient supply chains for niche APIs How C² PHARMA overcame the Digoxin challenge Posted on 6. June 20197. June 2019 by admin
FINANCIAL TIMES GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY CONFERENCE Posted on 22. November 201823. February 2021 by admin
CPhI 2017: C2 PHARMA acquires R&D synthesis services company and establishes cold-chain logistics spin-off Posted on 16. October 201723. February 2021 by admin